UNSPSC 51384702: Emorfazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H17N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V93U9DH62C, chemically known as 3(2h)-pyridazinone, 4-ethoxy-2-methyl-5-morpholino- but generally known as emorfazone, which bears US NIH Compound Identifier 3221. European Medicines Agency schedules Emorfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06511MIG. The term EMORFAZONE is an International Non-Proprietary Name.

UNSPSC 51384702 Emorfazone is a Commodity code representing pharmaceutical products purchased by state and local health agencies, counties, and state multistate cooperative purchasing alliances. The scope of work under this code covers the procurement of pharmaceuticals and over-the-counter products, including naloxone (opioid antagonists) and drug deactivation systems, as well as generic multi-source pharmaceuticals distributed through authorized wholesalers to state and local government health facilities. State and local governments buy finished pharmaceutical inventory for community health initiatives, emergency response programs, and institutional healthcare delivery, with vendors required to meet FDA compliance, current Good Manufacturing Practices certification, and Drug Supply Chain Security Act requirements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent procurement activity spans Florida, Texas, and Minnesota through a cooperative purchasing vehicle. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs for its pharmacy benefit initiative. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; vendors must supply products through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and pricing evaluation weights competitiveness at 75 percent.